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rate of failures, evaluation of treatment intensification by 
systemic components maybe warranted in patients with 
recurrent soft-tissue sarcomas.  
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Purpose or Objective: To report our long-term results with 
surgery, IOERT and postoperative EBRT in patients with soft-
tissue sarcomas of the upper extremity. 
 
Material and Methods: We performed a retrospective 
analysis of 37 patients suffering from soft-tissue sarcomas of 
the upper extremity, who received surgery, IOERT and 
postoperative EBRT at our institution. Median age was 61 
years (28-83) and median tumor size was 6 cm (1-15). 26 
patients (70%) presented in primary situation. Stage at 
presentation (UICC 7th) was as follows: IIa:43%, IIb:8%, 
III:43%, IV:5%. All patients suffered from high grade lesions 
(FNCLCC G2: 27%, G3:73%), predominantly MFH (51%). Gross 
total excision was achieved in all patients with free margins 
in 51% and microscopically positive margins in 49%. IOERT was 
applied to the tumor bed with a median dose of 15 Gy, using 
electron energies of 6-8 MeV and a median cone size of 8 cm. 
All patients received postoperative EBRT with a median dose 
of 45 Gy. 30% of the patients also received pre- and/or 
postoperative chemotherapy. 
 
Results: The median follow up was 78 months (6-231) for the 
entire cohort and 94 months (6-231) in survivors. Local 
failures were observed in 6 patients (16%), resulting in 
estimated 5-year and 10-year local control rates of 80%. 9 
patients (24%) showed distant failures, transferring into 
estimated 5-year and 10-year distant control rates of 71%. 
Overall treatment failure was observed in 14 patients (38%), 
of whom 5 failed locally only, 8 distant only and 1 combined, 
resulting in 5- and 10-year estimated FFTF rates of 55%.11 
patients have deceased, transferring into estimated 5-and 10-
year overall survival rates of 82% and 70%, respectively. 
Severe postoperative complications were rare (3%). Severe 
late toxicity was found in 11% of the patients. Preserved limb 
function without impairment in activities of daily living was 
achieved in 79% of the patients. 
 
Conclusion: Combination of surgery, IOERT and postoperative 
EBRT resulted in good local control and overall survival given 
the high rate of microscopically positive resections in this 
unfavourable patient cohort. Severe postoperative 
complications were rare compared to other sites.  
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Purpose or Objective: Cardiac and large vessel sarcomas are 
extremely rare neoplasms exhibiting aggressive behavior. 
Surgery is the most widely accepted treatment modality, but 
local recurrence and metastatic spread are common.The role 
of radiation ("definitive" or adjuvant) and chemotherapy is 
poorly-defined. In particular sparse data exists on the benefit 
of radiotherapy, and on the dose and technique required to 
achieve maximal benefit, with minimal toxicity. 
 
Material and Methods: Five patients with primary cardiac 
and great vessel sarcomas, diagnosed between 2010and 2013, 
were identified in our radiation oncology department 
database. 
We present here their clinical characteristics,dosimetric 
data, and outcomes. 
 
Results: All Patients analyzed had high grade sarcoma with 
various histologic subtypes and without metastatic 
spread.Sites of origin were left atrium (2), SVC, pulmonary 
artery and descending thoracic aorta.Four patients had 
positive margins after curative-intent surgery, while one was 
considered inoperable. Surgery included reconstruction with 
a graft in three cases (PTFE / Gore-Tex) and 
heartautotransplantation technique in one.One patient 
received neoadjuvant and adjuvant chemotherapy.All 
patients received fractionated radiotherapy utilizing IMRT 
with Simultaneous Integrated Boost (SIB) to a maximal dose 
of 60-65Gy, except for one who received 54 Gy utilizing a3D 
technique. Mean PTV was 419.23 (range: 163.99cm3-
631.95cm3).All patients completed the full course of 
treatment. Acute toxicity consisted mainly of fatigue and 
mild dysphagia, while long termevents were significant for 
NSTEMI in one patient (with local recurrence), and mild-
moderate pleural and pericardial effusions in another 
patient. With a median follow-up of 25 months (range:24-31), 
4/5 pts remain loco-regionally controlled (including the 
patient treated with definitive radiotherapy) and one had 
local recurrence (the patient who received 54Gy).One patient 
remains NED, three others developed metastatic disease, and 
one died of his local recurrent disease. 
 
Conclusion: Based on our experience, radiotherapy to a dose 
of 60-65Gy using IMRT/SIB can achieve very good local 
control in the adjuvant and possibly definitive setting in 
cardiac and large vessels HG sarcomas. This schedule is 
feasible and generally well tolerated. 
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Purpose or Objective: Proton beam therapy (PT) is an 
attractive tool in multimodality cancer care and of increasing 
interest especially for tumors in close proximity to critical 
structures or in particular sensitive tissues. First clinical 
results of patients with sarcomatous tumors treated at the 
West German Proton Therapy Center Essen (WPE) with regard 
to early toxicity are presented. 
 
Material and Methods: Between May 2013 and Oct 2015, 101 
patients (aged 0.9-84.6 y (median 13.8 y); 56% male) with 
sarcomas were prospectively enrolled in the registry studies 
“KiProReg” and “ProReg” at WPE. Histologies were 
rhabdomyosarcoma (n=38), chordoma/chondrosarcoma 
(n=28), EWING sarcoma (n=10), synovial sarcoma (n=4), 
osteosarcoma (n=3), malignant rhabdoid tumors (n=3), and 
miscellaneous (n=15). In 79% of the cohort, residual disease 
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was still present when starting PT after incomplete resection 
or biopsy only. Treatment sites were head and neck/base of 
skull (n=59), pelvis (n=19), spinal/paraspinal area (n=23). The 
median PT dose administered was 55.8 Gy (45.0 - 74.0 Gy) 
with a median number of 31 fractions (range 25-41). Mixed 
beam technique was delivered in 2 patients only. In 53.5% of 
the patients (48 children, 6 adults) concomitant 
chemotherapy was applied. Treatment related side-effects 
were classified according to CTCAE V4.0 grading system and 
were assessed weekly during PT and in all follow-up visits. 
 
Results: Median follow-up after first diagnosis was 10.6 
months (range 3.3 months to 10.5 years). During PT no or 
only mild to moderate (grade 1 to 2) additional acute side-
effects were documented in the majority of patients (n=79); 
predominantly erythema, alopecia, mucositis, fatigue, pain, 
and hematotoxicities when compared to baseline. In 28 
children, additional grade 3 side-effects occurred during PT; 
aplasia (n=10; all receiving concomitant chemotherapy), 
mucositis (n=7; all receiving concomitant chemotherapy), 
general disorder (n=5), nausea, skin ulceration, headache, 
diplopia, anorexia, and arthralgia (each n=1). Additional 
grade 4 side-effects during PT were only seen in one patient 
for blood/bone marrow (n=1) while receiving concomitant 
chemotherapy. So far, nine patients failed due to systemic 
(n=6) or local (n=3) recurrence or progression. Five of these 
patients died due to disease. 
In 73 patients, information on early-late effects after at least 
3 months is available. In this group one new grade 3 side 
effect (fatigue) revealed and one new hematotoxicity was 
documented while receiving concomitant chemotherapy. No 
grade 4 or 5 toxicity was observed. 
 
Conclusion: Current prospective and standardized data in 
sarcomatous tumor patients from WPE registry suggest good 
feasibility of the treatment even when high doses are 
administered at critical sites and sensitive tissues. However, 
longer FU is needed to understand the clinical benefit both in 
terms of late side effects and local control. 
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Purpose or Objective: Uterine Sarcomas represent 3-7% of 
Uterine Carcinomas. Stage, Grade, Histology and Lymph 
Nodes are important prognostic factors. Non metastatic 
patients had reduced local-regional failure (LRF) with 
radiotherapy. We evaluated 23 patients treated with 3D-
Conformal Irradiation (3D-CRT), Brachytherapy (BT), and 
Chemotherapy. 
 
Material and Methods: 23 PATIENTS WITH Stage I – III (FIGO 
2009) were analysed after TAH/BSO and peritoneal washings 
sampling. 15 patients with Malignant Mullerian Tumors 
(MMT), 2 Leiomyosarcomas (LMS), 1 grade 3 Stromal Sarcoma 
received adjuvant concurrent chemoradiation (CCRT). 5 
patients (3 MMT and 2 LMS) were treated for local relapse 
(Pelvic and/or Nodal involvement). 3D-CRT was given with a 
18MV Linac (59.40Gy in 1.8Gy/Fr, 5d/w). All patients 
received 1 MDR intracavitary insertion with 15Gy at the 
surface of the applicator. Concomitant Caelyx (12mg/m2) 
and CDDP (25mg/m2) were given the 1st and 4th day of each 
week respectively for a total of 6.6 weeks. In addition, 
Caelyx (20mg total) or CDDP (50mg total) were given 
simultaneously with MDR Brachytherapy depending on the 
hematologic toxicity of each patient.The above drugs were 
used as adjuvant treatment in every case for 4-6 Cycles after 
CCRT completion.  
 
Results: patients were deemed eligible for the study. The 
median age was 66 years. For the adjuvant treatment, 
13(72%) and 5(27%) patients were Stage I and II respectively. 
There have been 3/18(17%) locoregional relapses combined 
with lung metastases in 2 of them (LMS patients who died at 
24 and 26 months). Of the 5 patients with documented LRFs 2 
patients died at 24 and 31 months with disease progression. 
Overall 16/18(88%) with stage I/II and 3/5(60%) wth stage III 
are alive and disease free at a median follow up of 3 years 
(range 2-8 years). Leucopenia and CCRT enteritis/colitis were 
the most commonly reported toxicities. 
 
Conclusion: CCRT given for Uterine Sarcoma patients as 
adjuvant treatment or at LRF is a tolerable and effective 
treatment which needs verification in large phase II/III trials. 
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Purpose or Objective: Primary cardiac sarcomas are 
extremely rare and unfavourable malignancies. Surgery, 
although technically challenging, remains the mainstay of 
treatment. Only few data are available on the use of 
chemotherapy (CT) and radiotherapy (RT) for advanced 
disease. Basing on experiences with combined surgery, RT 
and CT in extremities sarcomas, we explored the feasibility 
of this multimodality approach in cardiac sarcomas. An 
update on tolerance and safety of treatment with focus on 
RT program is reported. 
 
Material and Methods: A retrospective analysis of a 
consecutive series of patients (pts) with unresectable disease 
referred to our Institute is reported. After oncologic-
cardiologic evaluation, anthracyclin-based CT was 
considered, followed by RT. IMRT-IGRT (Helical Tomotherapy) 
was used for more accurate tumor-conformal treatment 
while sparing the no-tumor-bearing surrounding heart tissue 
and to reduce the risk of radiation-induced heart disease 
(RIHD). Echocardiography was used in the treatment planning 
for organ motion and target-volume margin definition. Full-
dose RT with 45 Gy/25 frs with SIB up to 54 Gy was planned. 
Individualised dose constraints to left and right ventricles 
were included. 
 
Results: Between June 1998 and March 2013, 17 consecutive 
pts (M/F: 11/6, median age: 53yrs (25-72) with M0 cardiac 
sarcoma were referred to our Institute. Tumor location was 
right atrium in 8 pts, left atrium in 6, left ventricle in 2, 
pulmonary artery in 1pt; most common histologic type was 
angiosarcoma (62%). 8 pts had unresectable disease and 9 
had complete resection. 12 pts received 4 cycles of full-dose 
epirubicin 120mg/m2 and Ifosfamide 9g/m2 and G-CSF; 2 pts 
3 cycles of weekly Taxol 80 mg/m2. All pts underwent RT, 
median dose 54Gy (45-59.4Gy). Only 1 pt had moderate acute 
pericarditis and 2 had late toxicity (mild ejection fraction 
reduction). 3 pts with major response to CT-RT underwent 
successful complete surgical resection. At a median follow-up 
of 40 months (12-137), 9pts are alive and 6 are disease-free. 
 
Conclusion: In our experience, RT for cardiac sarcomas 
appeared to be feasible, also when combined with CT and 
surgery. Technological advances in RT planning and delivery 
and further insight into RT cardiac tolerance are crucial in 
minimizing the risk of RIHD. Further experience is needed to 
confirm these encouraging results. 
 
 
 
 
 
